NCT04591678View on ClinicalTrials.gov

Adults With SMA Treated With Nusinersen

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

May 14, 2021

Study Completion Date

June 25, 2021

Conditions
Spinal Muscular Atrophy
Interventions
DRUG

nusinersen

SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.

Trial Locations (1)

43210

The Ohio State University, Columbus

Sponsors

Collaborators (2)

Biogen
Cure SMA
All Listed Sponsors
collaborator

Biogen

INDUSTRY

collaborator

Cure SMA

OTHER

lead

Ohio State University

OTHER

NCT04591678 - Adults With SMA Treated With Nusinersen | Biotech Hunter | Biotech Hunter